Enanta Pharmaceuticals Inc
ENTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001177648
No open-market purchases or sales by Enanta Pharmaceuticals Inc insiders were filed in the last 90 days; 122 institutions reported holding it in 13F filings for Q2 2026, worth $397.2M in total; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Enanta Pharmaceuticals Inc changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 108 | 1 | 110 | +3 |
| Shares | 19.9M | 55.6K | 18.6M | −1.23M (−6.2%) |
| Value | $114.5M | $319.7K | $102.8M | −$11.3M (−9.9%) |
1 institution that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (20)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Nuveen, LLC | 56,671 | $312.8K | 0.00% |
| Ieq Capital, LLC | 41,997 | $231.8K | 0.00% |
| Graham Capital Management, L.P. | 20,022 | $110.5K | 0.00% |
| XTX Topco Ltd | 19,941 | $110.1K | 0.01% |
| Corton Capital Inc. | 13,921 | $76.8K | 0.25% |
| MetLife Investment Management | 13,079 | $72.2K | 0.00% |
| CI Private Wealth, LLC | 12,874 | $71.1K | 0.00% |
| Quantinno Capital Management LP | 11,017 | $60.8K | 0.00% |
| Schonfeld Strategic Advisors LLC | 10,800 | $59.6K | 0.00% |
| US Bancorp | 6,500 | $35.9K | 0.00% |
| Picton Mahoney Asset Management | 3,435 | $19.0K | 0.00% |
| GAMMA Investing LLC | 1,322 | $7.30K | 0.00% |
| Coldstream Capital Management Inc | 1,103 | $6.09K | 0.00% |
| Umb Bank N A | 978 | $5.40K | 0.00% |
| Comerica Bank | 950 | $5.24K | 0.00% |
| Red Tortoise LLC | 624 | $3.44K | 0.00% |
| Smartleaf Asset Management LLC | 434 | $2.48K | 0.00% |
| Massmutual Trust Co FSB | 386 | $2.13K | 0.00% |
| Headlands Technologies LLC | 361 | $1.99K | 0.00% |
| True Wealth Design, LLC | 351 | $1.94K | 0.00% |
Sold out (17)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Ra Capital Management, L.P. | 1,038,000 | $5.97M |
| Caligan Partners LP | 184,826 | $1.06M |
| Boothbay Fund Management, LLC | 85,649 | $492.5K |
| Prudential Financial Inc | 60,364 | $347.1K |
| Wellington Management Group LLP | 51,298 | $295.0K |
| Norges Bank | 40,700 | $234.0K |
| Oxford Asset Management LLP | 23,762 | $136.6K |
| Cubist Systematic Strategies, LLC | 20,255 | $116.5K |
| CIBC World Markets Inc. | 18,727 | $108.0K |
| Velan Capital Investment Management LP | 13,000 | $74.8K |
| Squarepoint Ops LLC | 11,558 | $66.5K |
| Engineers Gate Manager LP | 10,701 | $61.5K |
| Federated Hermes, Inc. | 8,534 | $49.1K |
| Aquatic Capital Management LLC | 3,510 | $20.2K |
| R Squared Ltd | 2,300 | $13.2K |
| IFP Advisors, Inc | 3 | $17 |
| Simplex Trading, LLC | 56 | $0 |
Not filed for Q1 2025 yet (1)
Institutions that held Enanta Pharmaceuticals Inc at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Nuveen Asset Management, LLC | 55,607 | $319.7K |